SPYRE THERAPEUTICS, INC. Share-based Payment Arrangement, Expense, Tax Benefit
SPYRE THERAPEUTICS, INC. (SYRE) reported Share-based Payment Arrangement, Expense, Tax Benefit of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense · last filed 2026-02-19
- SPYRE THERAPEUTICS, INC. share-based payment arrangement, expense, tax benefit for fiscal 2025 was $0.00.
- SPYRE THERAPEUTICS, INC. share-based payment arrangement, expense, tax benefit for fiscal 2024 was $0.00.
- SPYRE THERAPEUTICS, INC. share-based payment arrangement, expense, tax benefit for fiscal 2023 was $0.00.
- SPYRE THERAPEUTICS, INC. share-based payment arrangement, expense, tax benefit for fiscal 2022 was $0.00.
| Period end | Share-based Payment Arrangement, Expense, Tax Benefit 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-19 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-19 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-19 |
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 |
| 2021-12-31 | $0.00 10-K/A · filed 2024-11-18 |
| 2020-12-31 | $0.00 10-K · filed 2023-03-02 |
| 2019-12-31 | $0.00 10-K · filed 2022-03-08 |
| 2018-12-31 | $0.00 10-K · filed 2021-03-18 |
| 2017-12-31 | $0.00 10-K · filed 2020-02-24 |
| 2016-12-31 | $0.00 10-K · filed 2019-03-07 |
| 2015-12-31 | $0.00 10-K · filed 2018-03-13 |
| 2014-12-31 | $0.00 10-K · filed 2018-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |